Skip to main
LUCD

Lucid Diagnostics (LUCD) Stock Forecast & Price Target

Lucid Diagnostics (LUCD) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lucid Diagnostics Inc. is witnessing steady growth in its EsoGuard test volume, with a 2% year-over-year increase recorded in 3Q25, reflecting rising demand for its services. The company is expanding insurance coverage for EsoGuard, particularly with Medicare, which is expected to drive substantial revenue growth as it capitalizes on the increasing test volume and broader market accessibility. Additionally, positive developments from the MolDX CAC meeting indicate potential for favorable Medicare coverage decisions, further enhancing Lucid Diagnostics' financial prospects and market position.

Bears say

Lucid Diagnostics Inc. experienced a missed consensus revenue in the third quarter of 2025, contributing to a negative outlook for the company's stock. The company reported a pro forma net loss of $10.3 million, exceeding both its own estimates and consensus expectations, alongside a stable cash burn that resulted in approximately $47 million of pro forma cash remaining. Significant risks confront Lucid, including slow adoption rates for its EsoGuard product, potential insurance reimbursement challenges, and competitive pressures from emerging tests, all of which could adversely affect the company's financial stability and growth prospects.

Lucid Diagnostics (LUCD) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lucid Diagnostics (LUCD) Forecast

Analysts have given Lucid Diagnostics (LUCD) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Lucid Diagnostics (LUCD) has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lucid Diagnostics (LUCD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.